ArticleFrontiers in psychiatry2026
Proteome-wide Mendelian randomization and colocalization analyses identify potential biomarkers for schizophrenia.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We performed proteome-wide Mendelian randomization (MR) and colocalization analyses to explore the causal relationships between proteins and schizophrenia (SCZ). Methods: In the primary analysis, genetic instruments of 4,907 plasma protein from 35,559 Icelanders served as the exposure, summary statistics for SCZ (35,476 cases, 46,839 controls) Working Group of the Psychiatric Genomics Consortium (PGC) served as the outcome. The initial findings underwent sensitivity analyses and were externally validated using cis-pQTLs from the Fenland study (4,979 proteins, 10,708 participants) and UK Biobank Pharma Proteomics Project (UKB-PPP, 2923 proteins, 33,043 participants), and brain cis-eQTLs from Genotype-Tissue Expression (GTEx). Bayesian colocalization assessed shared causal variants. Protein-protein interactions with antipsychotic drug targets were explored. Results: In the primary analysis, genetically predicted levels of seven plasma proteins were significantly associated with SCZ risk: ADAM22 (OR = 0.85, Conclusion: This large-scale MR study provides robust evidence supporting causal roles for specific plasma proteins in SCZ pathogenesis, highlighting promising candidates for mechanistic studies and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.